Photonike Capital SA Overview
Photonike Capital SA is a Brussels-domiciled micro-cap holding company that has repositioned itself three times in sixteen years. It started as a photovoltaic developer, became an industrial turnaround investor, and now pursues a Belgian reinsurance and insurance strategy. It describes itself as a provider of "bespoke risk protection solutions" across industrial, financial and technological risk, and as a manager of turnaround processes. Its stated offering covers credit enhancement, market hedging and alternative-finance structures.
Its main live strategic project is obtaining a non-life reinsurance or insurance licence from the National Bank of Belgium (NBB), first applied for in 2020–2021 and still pending in 2026. In practice it is a closely held vehicle: about 80% of shares are held by two holding companies (Homepad SA and FFVentriglia Investment & Finance Ltd). Revenue is sporadic and contract-driven, with about EUR 1.76 million in FY2024 and almost none in earlier years. The shares trade thinly and far below the book values the company has asserted.
Company's own description. Photonike states that it is "a service provider of bespoke risk protection solutions (industrial, financial and technological) as well as a management company of industrial and financial turnaround processes" (Euronext/Cofisem company profile, updated 27 Jan 2025). Aggregator profiles derived from company material add that it "offers tailor made solutions for credit enhancement, market hedging, and alternative finance purposes" (Yahoo Finance; FMP).
Independent characterisation. On the evidence available, Photonike operates as a personal holding and deal vehicle rather than an operating company with a recurring business. Its activity has been organised around a small number of large, episodic projects:
-
Industrial turnarounds in Italy (2013 to late 2010s). It took control of Sandretto, the historic injection-moulding-machine maker at Pont Canavese near Turin, and invested in GBM Holding SpA. It financed these investments with bespoke quasi-equity instruments ("Photonike Special Swap 2017", "Special Convertible 2024", "Special Swap 2020") totalling about EUR 8.18 million, which were later converted to equity (2021 special board report). The Sandretto investment ended badly: trade press reported the company going into liquidation, and Photonike wrote down its Sandretto receivables in the FY2025 accounts (press release, 4 Jul 2026).
-
Insurance and reinsurance platform (2019 to present). In 2019 it announced an entry into European life insurance. It took a stake in Nucleus Life AG, a Liechtenstein life insurer, approved by the FMA Liechtenstein in July 2021, placed representatives on its board, and in January 2024 announced control of the holding vehicle Nucleus Holding II ScSP (Luxembourg). In 2020–2021 it applied to the NBB for a non-life reinsurance licence. The 2021–2025 business plan was built around this licence, but it has not been granted as of mid-2026. A 2022 attempt to buy an Italian non-life insurer (referred to in releases as the "Argo"/"AGA Italy" deal) has no publicly confirmed completion.
-
Contract-based risk-protection services (2024). In August 2024 it announced a contract worth EUR 1.7 million. This aligns closely with reported FY2024 revenue of EUR 1.76 million, but the link is an inference; the contract counterparty and scope are not disclosed.
-
Technology adjacency (2023 to present). It announced the "release of AESG-AI algorithms" in March 2023. In 2025 it invested about EUR 100,000 in an Italian AI developer that will build its risk-assessment software (press release, 30 Jun 2026).
Business and revenue model.
Strategy
Stated strategy themes (from company releases and the 2021–2025 plan):
-
Become a licensed Belgian non-life (re)insurer in credit, suretyship, financial-loss and legal-expenses classes. The 30 Jun 2026 release says the insurance team "has refined the licensing application criteria and appointed official liaison representatives with NBB".
-
Build an insurance group around Nucleus Life AG and Nucleus Holding II ScSP.
-
Apply AI to risk assessment, through the AESG-AI algorithms (2023) and outsourced risk-assessment software development (2025–2026).
-
Exit legacy Italian industrial exposure, including writing down Sandretto receivables (FY2025).
Initiatives in the last 24 months (Oct 2024 to Oct 2026):
ESG commitments: none disclosed. Cost programmes: none disclosed.
Medium-term targets. The only published financial targets are the Business & Development Plan 2021–2025 projections for the planned reinsurer:
Source: photonike.com, Business and Development Plan 2021–2025 (Retail Investors Release, 18 Mar 2021). Plan years were not mapped to calendar years in the extract.
Assessment. Because the licence was never obtained, none of these projections materialised. Actual net results over the plan period were losses of EUR 387–450k (FY2021–FY2022) and a profit of EUR 575k (FY2024). The plan should be regarded as superseded. No current guidance exists.
Products & Services
Photonike publishes no product catalogue with specifications or pricing. The offerings below are those named in company material.
Product Portfolio
| Offering | Description | Target customer | Year | Pricing | Source |
|---|---|---|---|---|---|
Bespoke risk-protection solutions | Tailor-made protection against industrial, financial and technological risks | Corporates | Ongoing | — | Euronext/Cofisem profile |
Credit enhancement | Structures that improve the credit standing of a client's obligations | Corporates, borrowers | Ongoing | — | Yahoo/FMP profile |
Market hedging | Hedging solutions against market risk | Corporates | Ongoing | — | Same |
Alternative finance | Non-bank financing structures, historically including proprietary "Special Swap" and "Special Convertible" instruments (2013–2014) | Investee companies, investors | 2013– | — | Same; 2021 Special Board Report |
Turnaround management | Management of industrial and financial restructurings (Sandretto precedent) | Distressed industrial companies | 2013– | — | Euronext/Cofisem profile |
Planned non-life reinsurance | Lines of business in the 2021–2025 plan include Class 14 Credit (insolvency, export credit, instalment credit, mortgages, agricultural credit), Class 15 Suretyship (direct, indirect), Class 16 Miscellaneous financial loss (employment risk, insufficient income, bad weather, loss of benefits, loss of market value, loss of rent/revenue, other financial loss) and Class 17 Legal expenses | Insurers, corporates | Planned since 2020; licence pending | Premium-based (projected only) | Business & Development Plan 2021–2025 |
Life insurance (through Nucleus Life AG) | Life-insurance products. A new product catalogue was launched in Feb 2024. | Retail and HNW clients | 2024 catalogue | — | Release, 26 Feb 2024 |
AESG-AI algorithms | Proprietary algorithms related to ESG/risk assessment | Internal / clients | Mar 2023 | — | Release, 24 Mar 2023 |
Risk-assessment software (in development) | AI-based risk-assessment tool being built by an Italian AI company in which Photonike invested about EUR 100k | Internal underwriting | 2025–2026 | Not applicable | Release, 30 Jun 2026 |
Captive insurance (exploratory) | Market commentary on captive insurance in France suggests interest in captive structures | Corporates | Sep 2023 | — | Release, 20 Sep 2023 |
“—” = not publicly disclosed.
Financial Narrative
Income statement
Source notes:
-
FY2021–FY2022 operating and net income: Cofisem/Euronext, with year alignment inferred. The prior years in the same series are FY2020 (operating -15, net -52) and FY2019 (operating +20, net -11).
-
FY2024 revenue, gross profit, other expenses and earnings: Simply Wall St, which shows EUR 1.8M revenue, EUR 0 cost of revenue, EUR 1.2M other expenses and EUR 576.4k earnings. Yahoo shows revenue of EUR 1.76M and net income of EUR 576.39k.
-
The company's AGM release (20 Feb 2026) gives FY2024 net profit as EUR 575,070. The discrepancy of about EUR 1.3k against aggregators is noted; the company figure is used.
-
FY2024 EPS of 0.0054 is from Simply Wall St and is consistent with 575,070 / 105.8M shares. Yahoo displays diluted EPS of -0.0000, an apparent data error.
-
The Cofisem table shows a "Net sales 34" value whose year cannot be reliably assigned, so it is excluded.
-
Dividends: none paid in any year reviewed (Boursorama: last dividend EUR 0.00).
Margins and growth
FY2024 net margin is computed as 575 / 1760 = 32.7%. Yahoo reports 32.77%. A 5-year revenue CAGR is not computable because revenue in earlier years was nil or undisclosed.
Balance sheet
Disclosed capital-structure data points outside the table:
-
The June 2021 Special Board Report proposed converting EUR 8,181,569 of "debt for shares to be issued" into equity at a nominal value of EUR 0.695 per share. This would take share capital to EUR 12,248,572.09, and then, after incorporating share premium, to EUR 73,523,618.91, with the stated aim of meeting reinsurer minimum paid-up capital thresholds. Further reserve and liability incorporations were executed in 2022–2023.
-
The company stated on 19 Dec 2020 that its FY2019 audit report confirmed a book value of EUR 6.65–7.00 per share. At about 105.8M shares that implies equity of roughly EUR 700M or more, which is irreconcilable with a EUR 11M market value and EUR 0.6M of annual profit. The asset values backing it, largely investments and receivables tied to Italian industrial positions, were written down at least in part in FY2025 (Sandretto receivables, 4 Jul 2026).
-
Simply Wall St rates the balance sheet as "mediocre" with "4 risks" flagged.
Cash flow
The FY2025 strategic investment is the approximately EUR 100k investment in an Italian AI developer (30 Jun 2026 release). No buyback programmes have been disclosed.
Ratios
None of these ratios can be computed from public data.
Commentary
Trend. The audited and aggregated record shows a company with no meaningful revenue from FY2019 to FY2022. It ran small operating losses of tens of thousands of euros, but net losses were materially larger (EUR -450k in FY2021 and EUR -387k in FY2022 on the inferred alignment). That gap points to financial charges, write-downs or investment-related losses below the operating line.
Inflection. FY2024 is the only year with substantial revenue: about EUR 1.76M at a 100% gross margin, producing net profit of EUR 575,070. Management described this as having "returned the company to profitability in 2024" (30 Jun 2026 release). The timing and size match the EUR 1.7M contract announced on 20 Aug 2024. The revenue therefore looks like a single-contract event, not evidence of a recurring earnings base.
Deterioration risk for FY2025. The 4 Jul 2026 release on the write-down of Sandretto receivables, followed by a "Financial Statements 2025 update" on 22 Sep 2026, strongly suggests FY2025 includes a material impairment. Neither the size of the write-down nor the FY2025 result was retrievable, so both are left blank rather than estimated.
Reporting discipline. Accounts have been chronically late:
-
FY2022 accounts were approved on 2 Jan 2024.
-
FY2023 accounts were delayed "for technical reasons" (17 Dec 2024) and approved on 22 Jul 2025, about 19 months after year-end.
-
FY2024 accounts were approved on 20 Feb 2026, about 14 months after year-end.
This lag is itself a material governance and credit signal.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Jurisdiction | Relationship | Activity | Status / source |
|---|---|---|---|---|
Photonike Capital SA | Belgium | Listed parent | Risk-protection services, holding, reinsurance licence applicant | Active |
Nucleus Holding II ScSP | Luxembourg | Control announced 8 Jan 2024 | Insurance holding vehicle | Ownership % not disclosed |
Nucleus Life AG | Liechtenstein | Investee; FMA approval Jul 2021; Ventriglia board chair from Oct 2022 | Life insurance. FY2023 net profit CHF 596,897 (release 18 Apr 2024). | Stake % not disclosed |
TriCap Assurance | — | Described as "subsidiary" in an Aug 2020 release | Insurance | Status not disclosed |
Italian AI developer (unnamed) | Italy | About EUR 100k investment in 2025 | Risk-assessment software | Name not disclosed |
Sandretto SpA | Italy | Former subsidiary | Injection-moulding machines | In liquidation per trade press; receivables written down FY2025 |
GBM Holding SpA | Italy | Former investee | — | Status not disclosed |
GlobaQ Industries Corporation | USA | Planned subsidiary at IPO (2010) | Solar-panel plant | No evidence it became operational |
“—” = not publicly disclosed.
Segment Overview
| Segment | FY2024 |
|---|---|
Total company revenue (EUR K) | 1,760 |
Risk-protection / structuring services (EUR K) | 1,760 |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (EUR K) | — | — | — | 1,760 | — |
Gross profit (EUR K) | — | — | — | 1,760 | — |
Other operating expenses (EUR K) | — | — | — | 1,200 | — |
Operating income (EUR K) | -38 | -35 | — | — | — |
Net income (EUR K) | -450 | -387 | — | 575 | — |
EPS basic (EUR) | — | — | — | 0.0054 | — |
Dividend per share (EUR) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2024 |
|---|---|
Gross margin (%) | 100 |
Net margin (%) | 32.7 |
Key Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dividends paid (EUR K) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (EUR K) | 0 | 0 | 0 | 0 | 0 |
Strategic investments (EUR K) | — | — | — | — | 100 |
Region Overview
| Region | FY2024 |
|---|---|
Total (EUR K) | 1,760 |
Share Price and Market Valuation
| Metric | FY2024 | FY2026 |
|---|---|---|
Observed share price (EUR) | 0.13 | 0.10 |
Market capitalisation (EUR Mn) | 13.75 | 11 |
Shares outstanding (M) | 105.8 | — |
Share Price & Returns
| Period | Return | Source / note |
|---|---|---|
1-year | -40.17% | Zonebourse snapshot (date of snapshot not confirmed) |
3-year | -63.16% | Same |
3-year (alternate snapshot) | -92.23% | Zonebourse CH (different date) |
Valuation Multiples
| Multiple | Photonike | Peer note |
|---|---|---|
P/E (FY2024) | About 18.4x | Simply Wall St/Yahoo show "–" |
EV/Sales | Not computable (net debt unknown) | Not applicable |
P/Sales | About 6.0x | Computed |
EV/EBITDA | Not computable | Not applicable |
P/B | Not computable on audited equity. On the company's 2020 claim of EUR 6.65–7.00 BVPS it would be about 0.015x, an implausible figure that indicates the claim should not be relied on. | Not applicable |
Item | Status | — |
Analyst consensus | None; no sell-side coverage | — |
Dividend history / policy | No dividends paid; no policy disclosed | — |
Buybacks | None authorised or disclosed | — |
Credit ratings (Moody's/S&P/Fitch) | None. Only a Dun & Bradstreet commercial rating of 5A2 (Feb 2024). | — |
Debt maturity profile | Not disclosed. Legacy instruments carried maturities of 2017, 2020 and 2024; these were proposed for conversion to equity in 2021. | — |
Daily price limits (Boursorama, Aug 2026) | Down limit EUR 0.0990, up limit EUR 0.1210 | — |
Liquidity | Zero volume on the last observed session; "capital échangé" 0.00% | — |
Analyst Conclusions
Management guidance. No current financial guidance has been given. The 2021–2025 business plan has expired unachieved. The only forward-looking statements are qualitative: pursuing the NBB licence and developing AI risk-assessment software (30 Jun 2026).
Consensus expectations. None; there is no analyst coverage.
Bull case
-
Licence optionality. The NBB process is ongoing, with refined criteria and appointed liaisons. Authorisation would turn a EUR 11M shell into a regulated carrier with the plan's modelled earnings power (Year-5 net profit EUR 10.96M), a large multiple of today's market value.
-
Demonstrated profitability. FY2024 showed the model can generate high-margin contract income (EUR 1.76M revenue, 32.7% net margin). Two or three similar contracts a year would support a sub-10x P/E.
-
Legacy clean-up. Writing down Sandretto receivables in FY2025 could mark the end of the Italian industrial overhang and simplify the equity story.
Bear case
-
Execution record. A solar plan (2010), the Sandretto turnaround, the Fiera di Roma bid, the Italian insurer acquisition (2022) and the Euronext Growth uplisting (2023) all failed or went unconsummated. The reinsurer licence has been pending for more than five years.
-
Transparency and governance. Accounts are approved 14–19 months late, one draft was unaudited, the auditor is unidentified, Euronext has issued a compliance notice, and asserted book values cannot be reconciled with reality.
-
Earnings quality. The FY2024 profit appears tied to a single EUR 1.7M contract, and the FY2025 accounts include impairments. Recurring earnings power is unproven.
Key catalysts and monitorables (next 12 months)
-
Final approved and audited FY2025 accounts, including the size of the Sandretto write-down and the resulting equity.
-
Any NBB decision on the (re)insurance licence.
-
Clarity on who manages the company after the March 2025 withdrawal.
-
Outcome of the Euronext trading-compliance matter.
-
New contract announcements comparable to August 2024.
-
Disclosure of the Nucleus Holding II ScSP stake and consolidated insurance economics.
-
Liquidity: whether trading resumes on a regular basis.
Analyst verdict
Photonike Capital SA is best understood as a closely controlled, sparsely disclosed holding vehicle whose public equity is a small appendage to a long-running ambition: becoming a licensed Belgian non-life reinsurer. Sixteen years after its 2010 debut as a solar developer, the company has cycled through renewable energy, Italian industrial turnarounds and insurance investments. Each phase was announced with considerable ambition, and few produced verifiable shareholder value.
The FY2024 return to profit, with net income of EUR 575,070, is real and documented by an AGM-approved account. However, it appears to rest on one EUR 1.7 million contract and cannot yet be extrapolated. The FY2025 accounts, now in draft and already "updated", carry a write-down of legacy Sandretto receivables. That is a reminder that the asset values underpinning past claims of multi-euro book value per share were not sound.
The investment case reduces to a binary option on regulatory authorisation, wrapped in significant governance discount:
-
control concentrated at about 80%;
-
a combined chair and CEO, alongside an ambiguous statement that management withdrew in March 2025;
-
accounts approved more than a year late, one draft unaudited and the current auditor unidentified;
-
an exchange compliance notice.
Liquidity is minimal, with days passing without trades, so even a correct thesis may be hard to monetise.
On the available evidence, Photonike does not meet basic institutional standards for investability: audited timely accounts, transparent capital, an independent board and tradable liquidity. A market value of about EUR 11 million represents roughly 18 times a single year's contract-driven profit, with no visibility on cash, debt or equity. That valuation is not cheap for the risk borne.
The stock should be regarded as speculative and unsuitable for institutional portfolios. It warrants reconsideration only if three things happen: audited FY2025 accounts clarify equity and liquidity, the NBB grants a licence, and governance reforms (an independent board, timely reporting and a named auditor) are put in place.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Role | Tenure | Background / notes |
|---|---|---|---|
Fausto M. Ventriglia | Chairman & CEO (per Cofisem/Euronext, Jan 2025; FMP; Simply Wall St) | Since at least 2013–2015. Shareholder of about 25% in the mid-2010s per La Notizia. | Sole administrator of Sandretto SpA (2014). Chairman of the Nucleus Life AG board from Oct 2022. Age and education not disclosed. |
Claudio Marati | Shareholder (0.82%); historically 16.6% holder | — | Board role not confirmed |
Claude Chapelnot | Investor contact | — | Listed as Euronext company contact |
Luciano Minerva, Roberto Moretti | Historical shareholders (16.6% each, mid-2010s) | — | Per La Notizia |
“—” = not publicly disclosed.
Governance Overview
| Indicator | Assessment |
|---|---|
Chair/CEO separation | No: combined role (Ventriglia) |
Committees | None disclosed |
Audit status | FY2023 draft published "Not Audited". Auditor for FY2022 onward not identified. |
Reporting timeliness | Poor: accounts approved 12–19 months after year-end |
Exchange scrutiny | Euronext notice on "trading compliance of shares" (15 Sep 2025). |
Market communication | Company issued a "warning for fake news" about itself on an investment forum (7 Feb 2024) |
Uplisting | Euronext Growth move announced and then abandoned within 4 weeks (Oct 2023) |
Major Shareholders
| Holder | Stake (%) | Type |
|---|---|---|
Homepad SA | 68.14 | Holding company (beneficial owner not disclosed) |
FFVentriglia Investment & Finance Ltd | 12.26 | Holding company, apparently linked to the Chairman/CEO by name |
Claudio Marati | 0.82 | Individual |
Fausto M. Ventriglia (direct) | 0.70 | Chairman & CEO |
Free float (residual) | about 18.08 | Computed |
Competitive Landscape
Competitors by Segment
| Area | Competitors | Relative positioning |
|---|---|---|
Credit and suretyship (re)insurance | Allianz Trade, Atradius, Coface, Credendo (Belgium), Swiss Re, Munich Re, SCOR | Photonike is unlicensed and has no premium base; these are global incumbents with billions in premiums |
Bespoke risk transfer / structured solutions | Swiss Re Corporate Solutions, Munich Re (Risk Solutions), AXA XL, Marsh (captives) | Photonike has no ratings, no capital disclosure and no track record |
Captive management (France/Belgium) | Marsh Captive Solutions, Aon Captive & Insurance Management | Exploratory only |
Liechtenstein life insurance (Nucleus Life AG) | Liechtenstein Life, Prisma Life, Swiss Life (Liechtenstein) | Nucleus Life is small (FY2023 profit CHF 0.6M) |
Listed small-cap holding/turnaround vehicles | Various Euronext Access/Growth holdings | Comparable in scale only |
Peer Comparison FY2024
| Metric | Photonike FY2024 | Coface FY2024 | SCOR FY2024 |
|---|---|---|---|
Revenue | EUR 1.76M | About EUR 1.8bn | About EUR 20bn |
Net margin | 32.7% | About 13% | Not meaningful (net loss in 2024) |
Growth | Not meaningful | Low single digit | — |



